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Abstracts / Biol Blood Marrow Transplant 20 (2014) S211eS256 S237demonstrated a regenerating marrow, with no evidence for
residual disease and 100 % donor chimerism.
Patient No.3 presented with refractory cytopenia with
marrow dysgranulopoiesis and dysmegakaryopoiesis
(Childhood MDS). She underwent a 9/10 HLA-DQ MUD
transplant. Post-transplant course was complicated by C
difﬁcile infection and acute grade 1 skin GVHD. At day 30 she
had 100 % donor chimerism.
Conclusion: Germline GATA2 mutations are associated with
a high frequency of MDS/AML. We describe a family with a
non-zinc ﬁnger GATA2 mutation causing MDS/AML, pro-
found B/NK deﬁciency and viral warts and describe the
successful role for allo-HCT in this setting.364
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ABO incompatibility among patients (pts) undergoing allo-
geneic stem cell transplant (ASCT) is associated with delayed
engraftment and post-transplant pure red cell aplasia
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Da
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47 CML M->M 10/10MUD B-/A+
Bi-Dir
Cy/TBI PBSCT No Neg PL
41 MDS M->M 10/10MUD AB+/O+ Cy/Bu PBSCT No 256 PL
33 MDS M->M 10/10MUD A+/O+ Pent/TBI PBSCT GI 1 Neg DaAfter due IRB approval we retrospectively analyzed the
prevalence and outcome of PT-PRCA among pts undergoing
ASCT at Mayo Clinic, Rochester between 1/1/2000 and 9/
30/2013. Out of 886 ASCT done during the period, we
identiﬁed 53(6%) pts with major ABO and 24 (3%) pts with
bi-directional ABO incompatibility. Twelve patients (1%)
developed PT-PRCA; 11 had major ABO incompatibility
while one had a bidirectional mismatch. All pts received
red cell depleted stem cells and there were no cases of
acute hemolysis. Six pts underwent reduced intensity
conditioning.
Median time to diagnosis of PT-PRCA was 42 days (23-
67), with reticulocytopenia and renewed transfusion
dependance. Pts were initially managed with immuno-
suppression taper and EPO supplementation. Refractory
cases were treated with plasmapheresis (4), rituximab (6)
and DLI (1). One pt relapsed and 2 pts died (both sepsis)
prior to resolution of PT-PRCA. After excluding these
pts median time to resolution of PT-PRCA was 113 days
(13-429).
PT-PRCA is not an uncommon complication of major ABO
incompatible ASCT. However it is relatively less common in
patients with bi-directional incompatibility. PT-PRCA results
in renewed transfusion dependance. Immunosuppression
taper and/or immunomodulation can serve as effective
treatment strategies.(In
dition
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